Search

… Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues across multiple … against a key Axiomer patent protecting ADAR-mediated RNA editing Well-capitalized with €139 M, in cash and cash …

… to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple therapeutic …

… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company …

… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual …

… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform today announced that Company …

… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced the Annual …

… programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of …

… company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully … filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in …

… Officer role, with leadership oversight of Axiomer ® RNA-editing platform technology John Maraganore, PhD, former …